药物洗脱支架术后房颤患者的治疗:NOAC单药对比联合治疗
该多中心、随机、开放标签、非劣效性试验在韩国纳入960例房颤且药物洗脱支架植入至少1年的患者,1:1随机接受NOAC单药(482例)或NOAC联合氯吡格雷(478例)。主要终点为12个月净不良临床事件复合终点(全因死亡、心肌梗死、支架血栓、卒中、系统性栓塞、大出血或临床相关非大出血)。单药组主要终点事件46例(Kaplan-Meier估计9.6%),联合组82例(17.2%),绝对差异-7.6个百分点(95.2%CI -11.9至-3.3;非劣效性P<0.001),风险比0.54(95.2%CI 0.37至0.77;优效性P<0.001)。大出血或临床相关非大出血单药组25例(5.2%) vs 联合组63例(13.2%),风险比0.38(95%CI 0.24至0.60)。
要点
- 药物洗脱支架植入至少1年的房颤患者,NOAC单药12个月净不良临床事件9.6% vs NOAC联合氯吡格雷17.2%,绝对差异-7.6个百分点(95.2%CI -11.9至-3.3),非劣效性P<0.001。
- NOAC单药较联合氯吡格雷降低净不良临床事件(HR 0.54;95.2%CI 0.37至0.77;优效性P<0.001)。
- 大出血或临床相关非大出血:NOAC单药5.2% vs 联合氯吡格雷13.2%(HR 0.38;95%CI 0.24至0.60)。
- 该试验为多中心、随机、开放标签、非劣效性设计,非劣效界值3.0个百分点,纳入药物洗脱支架植入至少1年后的房颤患者。
- 试验在韩国进行,共960例患者随机,平均年龄71.1岁,女性占21.4%。
适用人群与场景
- 房颤且药物洗脱支架植入至少1年的患者,来自韩国多中心随机试验,共960例随机(单药组482例,联合组478例)。
- 平均年龄71.1岁,女性占21.4%。
处置流程与药物剂量
- NOAC单药组:仅接受NOAC治疗。
- 联合治疗组:接受NOAC联合氯吡格雷治疗。
研究设计与关键结果
- 多中心、随机、开放标签、非劣效性试验,在韩国纳入960例房颤且药物洗脱支架植入至少1年的患者,1:1随机至NOAC单药(482例)或NOAC联合氯吡格雷(478例)。
- 主要终点为12个月净不良临床事件(全因死亡、心肌梗死、支架血栓、卒中、系统性栓塞、大出血或临床相关非大出血的复合终点),非劣效界值3.0个百分点。
- 主要终点:单药组46例(Kaplan-Meier估计9.6%) vs 联合组82例(17.2%),绝对差异-7.6个百分点(95.2%CI -11.9至-3.3;非劣效性P<0.001),风险比0.54(95.2%CI 0.37至0.77;优效性P<0.001)。
- 大出血或临床相关非大出血:单药组25例(5.2%) vs 联合组63例(13.2%),风险比0.38(95%CI 0.24至0.60)。
证据类型、等级与局限
- 证据类型:多中心、随机、开放标签、非劣效性试验。
- 非劣效界值为3.0个百分点。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于房颤且药物洗脱支架植入至少1年的患者,NOAC单药在12个月净不良临床事件上不劣于NOAC联合氯吡格雷,且大出血或临床相关非大出血更少(5.2% vs 13.2%)。
- 作者结论:NOAC单药不劣于联合治疗用于净不良临床事件。
指南或共识出处
- ADAPT AF-DES试验(ClinicalTrials.gov NCT04250116),由Cardiovascular Research Center和Samjin Pharmaceutical资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite guideline recommendations, evidence for the use of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting stent remains limited.
METHODS: In this multicenter, randomized, open-label, noninferiority trial in South Korea, we assigned patients with atrial fibrillation who had undergone the implantation of a drug-eluting stent at least 1 year earlier in a 1:1 ratio to receive NOAC monotherapy or combination therapy (NOAC plus clopidogrel). The primary end point was net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, systemic embolism, or major bleeding or clinically relevant nonmajor bleeding at 12 months. The noninferiority margin was 3.0 percentage points.
RESULTS: A total of 960 patients underwent randomization: 482 patients to receive monotherapy and 478 to receive combination therapy. The mean age of the patients was 71.1 years, and 21.4% were women. At 12 months, a primary end-point event had occurred in 46 patients (Kaplan-Meier estimate, 9.6%) in the monotherapy group and in 82 patients (Kaplan-Meier estimate, 17.2%) in the combination-therapy group, for an absolute difference of -7.6 percentage points (95.2% confidence interval [CI], -11.9 to -3.3; P<0.001 for noninferiority) and a hazard ratio of 0.54 (95.2% CI, 0.37 to 0.77; P<0.001 for superiority). Major bleeding or clinically relevant nonmajor bleeding occurred in 25 patients (5.2%) in the monotherapy group and in 63 patients (13.2%) in the combination-therapy group (hazard ratio, 0.38; 95% CI, 0.24 to 0.60).
CONCLUSIONS: Among patients with atrial fibrillation who had undergone implantation of a drug-eluting stent at least 1 year earlier, NOAC monotherapy was noninferior to combination therapy for net adverse clinical events. (Funded by Cardiovascular Research Center and Samjin Pharmaceutical; ADAPT AF-DES ClinicalTrials.gov number, NCT04250116.).
参考来源
- Lee SJ, Yu HT, Lee YJ, et al. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. N Engl J Med. 2025. PMID: 41211917. doi:10.1056/NEJMoa2512091
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。